20/20 OptimEyes is a McMaster University spinout creating highly effective drug delivery systems to treat ocular conditions.
We are currently commercializing an improved eye drop that allows for less frequent dosing, which is more convenient for patients, but more importantly reduces side effects of current treatments.
This technology is patent pending, with a unique triblock copolymer providing its favourable properties. Our lead indication is dry eye disease, with glaucoma and ocular infections also being explored.
We have developed a new mucoadhesive drug delivery vehicle that will be used to deliver Cyclosporine A, the only drug that is currently FDA approved for treating dry eye.
This condition affects 10-20% of the population, and limits their ability to participate in outdoor activities, use a computer, or wear contact lenses.
Company Details
- Address
- Mcmaster Innovation Park, 175 Longwood Road South #305,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://2020optimeyes.ca/
- Keywords
- Hamilton.
- HQ
- Hamilton, Ontario
2020 Optimeyes Questions
2020 Optimeyes's website is http://2020optimeyes.ca/
2020 Optimeyes's LinkedIn profile is https://ca.linkedin.com/company/2020optimeyes
2020 Optimeyes's industry is
Biotechnology Research
2020 Optimeyes's top competitors are
Lexingworth Capital,
Machealthice,
20/20 Optimeyes Technologies,
Astrazeneca,
Halohealth,
Prova Innovations Ltd..
2020 Optimeyes's categories are Biotechnology Research
